Syngene International (Syngene) today announced the acquisition of its first biologics site in the USA - fitted with multiple monoclonal antibody (mAbs) manufacturing lines. The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.), will expand Syngene`s growing global biologics footprint to better serve its customers across both human and animal health market segments. The new site will increase Syngene`s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. Additionally, it will provide Syngene`s customers with continuity of supply from its four development and manufacturing facilities located in India and North America, offering services ranging from cell line development, process optimization and both clinical and commercial supply. Syngene`s investment in its first facility in the United States marks a strategic commitment to the US market, with significant benefits for the local economy and the broader life sciences industry. The facility is expected to create jobs, stimulate local economic activity, and strengthen domestic biologics manufacturing capabilities, while also contributing to pharmaceutical innovation and supply chain resilience. This investment highlights the potential for deeper economic collaboration between India and the United States, fostering sustained economic growth and advancing the shared goal of bolstering critical healthcare infrastructure. Powered by Capital Market - Live News

Net profit of Syngene International rose 17.58% to Rs 131.10 crore in the quarter ended December 2024 as against Rs 111.50 crore during the previous quarter ended December 2023. Sales rose 10.57% to Rs 943.70 crore in the quarter ended December 2024 as against Rs 853.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales943.70853.50 11 OPM %30.0527.12 - PBDT289.50250.00 16 PBT180.80141.90 27 NP131.10111.50 18 Powered by Capital Market - Live News

Syngene International will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live News

Net profit of Syngene International declined 8.93% to Rs 106.10 crore in the quarter ended September 2024 as against Rs 116.50 crore during the previous quarter ended September 2023. Sales declined 2.10% to Rs 891.00 crore in the quarter ended September 2024 as against Rs 910.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales891.00910.10 -2 OPM %27.4727.92 - PBDT248.20262.70 -6 PBT137.30158.10 -13 NP106.10116.50 -9 Powered by Capital Market - Live News

The Board of Syngene International at its meeting held on 23 October 2024 has approved the following change in management:Resignation of Sibaji Biswas, Executive Director and Chief Financial Officer (Key Managerial Personnel) from the services of the Company with effect from 30 November 2024. Appointment of Deepak Jain as the Chief Financial Officer and a Key Managerial Personnel of the Company effective from 01 December 2024. Appointment of Dr. Jayashree Aiyar as Chief Scientific Officer and a member of the Executive Committee (Senior Management Personnel) of the Company effective from 23 October 2024.Powered by Capital Market - Live News